1. Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer
- Author
-
Takashi Iguchi, Yasuo Kohjimoto, Kazuro Kikkawa, Isao Hara, Yuya Iwahashi, Hiroyuki Koike, Haruka Miyai, Shimpei Yamashita, Satoshi Nishizawa, Nagahide Matsumura, and Keizo Hagino
- Subjects
Male ,medicine.medical_specialty ,Multivariate analysis ,Urology ,medicine.medical_treatment ,Science ,Kaplan-Meier Estimate ,Cystectomy ,Article ,Psoas Muscles ,03 medical and health sciences ,0302 clinical medicine ,Muscular Diseases ,Hounsfield scale ,Carcinoma ,Humans ,Medicine ,Postoperative Period ,030212 general & internal medicine ,Cancer ,Aged ,Neoplasm Staging ,Retrospective Studies ,Multidisciplinary ,Bladder cancer ,business.industry ,Proportional hazards model ,Fatty Acids ,Prognosis ,medicine.disease ,Oncology ,Urinary Bladder Neoplasms ,Quartile ,030220 oncology & carcinogenesis ,Female ,Neoplasm Grading ,Tomography, X-Ray Computed ,business ,Biomarkers - Abstract
This study aims to evaluate the influence of myosteatosis on survival of patients after radical cystectomy (RC) for bladder cancer. We retrospectively identified 230 patients who underwent RC for bladder cancer at our three institutions between 2009 and 2018. Digitized free-hand outlines of the left and right psoas muscles were made on axial non-contrast computed tomography images at level L3. To assess myosteatosis, average total psoas density (ATPD) in Hounsfield Units (HU) was also calculated as an average of bilateral psoas muscle density. We compared cancer-specific survival (CSS) between high ATPD and low ATPD groups and performed cox regression hazard analyses to identify the predictors of CSS. Median ATPD was 44 HU (quartile: 39–47 Hounsfield Units). Two-year CSS rate in overall patients was 76.6%. Patients with low ATPD (P = 0.01) than patients with high ATPD (≥ 44 HU). According to multivariate analysis, significant independent predictors of poor CSS were: Eastern Cooperative Oncology Group performance status ≥ 1 (P = 0.03), decreasing ATPD (P = 0.03), non-urothelial carcinoma (P = 0.01), pT ≥ 3 (P P
- Published
- 2020